Skip to main content
Erschienen in: World Journal of Pediatrics 1/2024

17.01.2024 | Editorial

Current Mycoplasma pneumoniae epidemic among children in Shanghai: unusual pneumonia caused by usual pathogen

verfasst von: Xiao-Bo Zhang, Wen He, Yong-Hao Gui, Quan Lu, Yong Yin, Jian-Hua Zhang, Xiao-Yan Dong, Ying-Wen Wang, Ying-Zi Ye, Hong Xu, Jia-Yu Wang, Bing Shen, Dan-Ping Gu, Li-Bo Wang, Yi Wang

Erschienen in: World Journal of Pediatrics | Ausgabe 1/2024

Einloggen, um Zugang zu erhalten

Excerpt

Mycoplasma pneumoniae (M. pneumoniae), primarily transmitted through respiratory droplets when infected individuals cough or sneeze, is a common cause of community-acquired pneumonia, especially among school-age children and adolescents. The infection occurs endemically with an epidemic peak every few years. The worldwide incidence confirmed by direct test methods was reported to be 8.61% between 2017 and 2020 across all age groups [1]. During the coronavirus disease 2019 (COVID-19) pandemic, from 2020 to 2021, the incidence decreased to 1.69% due to nonpharmaceutical interventions (NPIs) [1]. Until 2022, despite the relaxation or discontinuation of NPIs, reductions in incidence continued to be seen in 20 countries across Europe, Asia, the Americas, and Oceania [2]. In China, there was initially a consistent trend in the number of patients with Mycoplasma pneumoniae pneumonia (MPP) both before and after the pandemic [36]. After that, an unusually different pattern was observed starting in 2021. Typically, M. pneumoniae infection presents with symptoms of fever and cough, often accompanied by sore throat, coryza, and occasionally, headache [7]. From April 2020 to early December 2022, has been among the strictest, longest approaches to tackling the pandemic anywhere in the world. Such a long-term NPI has caused a potential for more severe respiratory pathogens epidemics due to a so-called immunity debt. With the lifting of NPI policy, China has experienced peaks in influenza viruses, respiratory syncytial virus (RSV), and M. pneumoniae over the past year. Notably, M. pneumoniae has undergone a prolonged non-seasonal epidemic, gaining prevalence from April and reaching its peak from October to November. The vast majority of the children, especially infants and preschool children, who have not been exposed to these respiratory pathogens, become a susceptible population that is so large that a sizable unseasonal outbreak occurs when a previously usual respiratory pathogen begins circulating. Therefore, the recently reported spike in respiratory illnesses, especially pneumonia in children is mostly caused by M. pneumoniae infection. Additionally, macrolide-resistant M. pneumoniae infection also complicates the clinical treatment of this MPP epidemic [810]. …
Literatur
1.
Zurück zum Zitat Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022;27:2100746.CrossRefPubMedPubMedCentral Meyer Sauteur PM, Beeton ML, Uldum SA, Bossuyt N, Vermeulen M, Loens K, et al. Mycoplasma pneumoniae detections before and during the COVID-19 pandemic: results of a global survey, 2017 to 2021. Euro Surveill. 2022;27:2100746.CrossRefPubMedPubMedCentral
2.
Zurück zum Zitat Meyer Sauteur PM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML. Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? Lancet Microbe. 2022;3:e897.CrossRefPubMed Meyer Sauteur PM, Chalker VJ, Berger C, Nir-Paz R, Beeton ML. Mycoplasma pneumoniae beyond the COVID-19 pandemic: where is it? Lancet Microbe. 2022;3:e897.CrossRefPubMed
3.
Zurück zum Zitat Zhang LN, Cao L, Meng LH. Pathogenic changes of community-acquired pneumonia in a children’s hospital in Beijing, China before and after COVID-19 onset: a retrospective study. World J Pediatr. 2022;18:746–52.CrossRefPubMedPubMedCentral Zhang LN, Cao L, Meng LH. Pathogenic changes of community-acquired pneumonia in a children’s hospital in Beijing, China before and after COVID-19 onset: a retrospective study. World J Pediatr. 2022;18:746–52.CrossRefPubMedPubMedCentral
4.
Zurück zum Zitat Li X, Li T, Chen N, Kang P, Yang J. Changes of Mycoplasma pneumoniae prevalence in children before and after COVID-19 pandemic in Henan. China J Infect. 2023;86:256–308.PubMed Li X, Li T, Chen N, Kang P, Yang J. Changes of Mycoplasma pneumoniae prevalence in children before and after COVID-19 pandemic in Henan. China J Infect. 2023;86:256–308.PubMed
5.
Zurück zum Zitat Chen J, Zhang J, Lu Z, Chen Y, Huang S, Li H, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic. Microbiol Spectr. 2022;10:e0155021.CrossRefPubMed Chen J, Zhang J, Lu Z, Chen Y, Huang S, Li H, et al. Mycoplasma pneumoniae among Chinese outpatient children with mild respiratory tract infections during the coronavirus disease 2019 pandemic. Microbiol Spectr. 2022;10:e0155021.CrossRefPubMed
6.
Zurück zum Zitat Li L, Guo P, Ma J, Sun H, Mei S. Impact of COVID-19 on the epidemiological features of Mycoplasma pneumoniae infection in children with community-acquired pneumonia in Henan. China Microbiol Spectr. 2023;11:e0491122.CrossRefPubMed Li L, Guo P, Ma J, Sun H, Mei S. Impact of COVID-19 on the epidemiological features of Mycoplasma pneumoniae infection in children with community-acquired pneumonia in Henan. China Microbiol Spectr. 2023;11:e0491122.CrossRefPubMed
7.
Zurück zum Zitat Rogozinski LE, Alverson BK, Biondi EA. Diagnosis and treatment of Mycoplasma pneumoniae in children. Minerva Pediatr. 2017;69:156–60.CrossRefPubMed Rogozinski LE, Alverson BK, Biondi EA. Diagnosis and treatment of Mycoplasma pneumoniae in children. Minerva Pediatr. 2017;69:156–60.CrossRefPubMed
8.
Zurück zum Zitat Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res. 2022;241:1–12.CrossRefPubMed Peluso MJ, Donatelli J, Henrich TJ. Long-term immunologic effects of SARS-CoV-2 infection: leveraging translational research methodology to address emerging questions. Transl Res. 2022;241:1–12.CrossRefPubMed
9.
Zurück zum Zitat Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021;54:557–65.CrossRefPubMed Tsai TA, Tsai CK, Kuo KC, Yu HR. Rational stepwise approach for Mycoplasma pneumoniae pneumonia in children. J Microbiol Immunol Infect. 2021;54:557–65.CrossRefPubMed
10.
Zurück zum Zitat Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, et al. Pediatric infectious disease group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51:418–23.CrossRefPubMedPubMedCentral Cohen R, Ashman M, Taha MK, Varon E, Angoulvant F, Levy C, et al. Pediatric infectious disease group (GPIP) position paper on the immune debt of the COVID-19 pandemic in childhood, how can we fill the immunity gap? Infect Dis Now. 2021;51:418–23.CrossRefPubMedPubMedCentral
11.
Zurück zum Zitat Liu GB, Gu Y, Wang YW, Wang CQ, Ma J, Zeng M, et al. Clinical experiences in the management of critically ill patients with COVID-19 in a designated children’s hospital in China. World J Pediatr. 2023;19;605–8.CrossRefPubMedPubMedCentral Liu GB, Gu Y, Wang YW, Wang CQ, Ma J, Zeng M, et al. Clinical experiences in the management of critically ill patients with COVID-19 in a designated children’s hospital in China. World J Pediatr. 2023;19;605–8.CrossRefPubMedPubMedCentral
12.
Zurück zum Zitat China National Clinical Research Center of Respiratory Diseases; Respiratory Department of Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, China; Respiratory Branch of Chinese Pediatric Society of Chinese Medical Association. Chinese guideline for the diagnosis and treatment of childhood mycoplasma pneumoniae pneumonia (2023). Infect Dis Info. 2023;36:291–7. China National Clinical Research Center of Respiratory Diseases; Respiratory Department of Beijing Children’s Hospital, Capital Medical University; National Center for Children’s Health, China; Respiratory Branch of Chinese Pediatric Society of Chinese Medical Association. Chinese guideline for the diagnosis and treatment of childhood mycoplasma pneumoniae pneumonia (2023). Infect Dis Info. 2023;36:291–7.
13.
Zurück zum Zitat Liu YN, Zhang YF, Xu Q, Qiu Y, Lu QB, Wang T, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. Lancet Microbe. 2023;4:e330–9.CrossRefPubMed Liu YN, Zhang YF, Xu Q, Qiu Y, Lu QB, Wang T, et al. Infection and co-infection patterns of community-acquired pneumonia in patients of different ages in China from 2009 to 2020: a national surveillance study. Lancet Microbe. 2023;4:e330–9.CrossRefPubMed
14.
Zurück zum Zitat Wang L, Feng Z, Zhao M, Yang S, Yan X, Guo W, et al. A comparison study between GeXP-based multiplex-PCR and serology assay for Mycoplasma pneumoniae detection in children with community acquired pneumonia. BMC Infect Dis. 2017;17:518.CrossRefPubMedPubMedCentral Wang L, Feng Z, Zhao M, Yang S, Yan X, Guo W, et al. A comparison study between GeXP-based multiplex-PCR and serology assay for Mycoplasma pneumoniae detection in children with community acquired pneumonia. BMC Infect Dis. 2017;17:518.CrossRefPubMedPubMedCentral
16.
Zurück zum Zitat Kumar S. Mycoplasma pneumoniae: a significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. Indian J Med Res. 2018;147:23–31.CrossRefPubMedPubMedCentral Kumar S. Mycoplasma pneumoniae: a significant but underrated pathogen in paediatric community-acquired lower respiratory tract infections. Indian J Med Res. 2018;147:23–31.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Wen J, Su Y, Sun H, Zhang H, Li H. The combination of initial markers to predict refractory Mycoplasma pneumoniae pneumonia in Chinese children: a case control study. Respir Res. 2021;22:89.CrossRefPubMedPubMedCentral Wen J, Su Y, Sun H, Zhang H, Li H. The combination of initial markers to predict refractory Mycoplasma pneumoniae pneumonia in Chinese children: a case control study. Respir Res. 2021;22:89.CrossRefPubMedPubMedCentral
18.
Zurück zum Zitat Zheng Y, Hua L, Zhao Q, Li M, Huang M, Zhou Y, et al. The level of D-dimer is positively correlated with the severity of Mycoplasma pneumoniae pneumonia in children. Front Cell Infect Microbiol. 2021;11:687391.CrossRefPubMedPubMedCentral Zheng Y, Hua L, Zhao Q, Li M, Huang M, Zhou Y, et al. The level of D-dimer is positively correlated with the severity of Mycoplasma pneumoniae pneumonia in children. Front Cell Infect Microbiol. 2021;11:687391.CrossRefPubMedPubMedCentral
19.
Zurück zum Zitat Huang X, Li D, Liu F, Zhao D, Zhu Y, Tang H. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2021;21:14.CrossRefPubMedPubMedCentral Huang X, Li D, Liu F, Zhao D, Zhu Y, Tang H. Clinical significance of D-dimer levels in refractory Mycoplasma pneumoniae pneumonia. BMC Infect Dis. 2021;21:14.CrossRefPubMedPubMedCentral
20.
Zurück zum Zitat Chen S, Ding Y, Vinturache A, Gu H, Lu M, Ding G. Pulmonary embolism associated with mycoplasma in a child. Lancet Infect Dis. 2020;20:1347.CrossRefPubMed Chen S, Ding Y, Vinturache A, Gu H, Lu M, Ding G. Pulmonary embolism associated with mycoplasma in a child. Lancet Infect Dis. 2020;20:1347.CrossRefPubMed
21.
Zurück zum Zitat Zhang T, Zheng J, Wang H, Xu Y, Ning J, Cai C. Case report: cardiac multiple thrombus and pulmonary embolism associated with Mycoplasma pneumonia infection in a child. Front Pediatr. 2022;10:959218.CrossRefPubMedPubMedCentral Zhang T, Zheng J, Wang H, Xu Y, Ning J, Cai C. Case report: cardiac multiple thrombus and pulmonary embolism associated with Mycoplasma pneumonia infection in a child. Front Pediatr. 2022;10:959218.CrossRefPubMedPubMedCentral
22.
Zurück zum Zitat Wan GH, Huang CG, Chung FF, Lin TY, Tsao KC, Huang YC. Detection of common respiratory viruses and Mycoplasma pneumoniae in patient-occupied rooms in pediatric wards. Medicine (Baltimore). 2016;95:e3014.CrossRefPubMed Wan GH, Huang CG, Chung FF, Lin TY, Tsao KC, Huang YC. Detection of common respiratory viruses and Mycoplasma pneumoniae in patient-occupied rooms in pediatric wards. Medicine (Baltimore). 2016;95:e3014.CrossRefPubMed
23.
Zurück zum Zitat Mina MJ, Burke RM, Klugman KP. Estimating the prevalence of coinfection with influenza virus and the atypical bacteria Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis. 2014;33:1585–9.CrossRefPubMedPubMedCentral Mina MJ, Burke RM, Klugman KP. Estimating the prevalence of coinfection with influenza virus and the atypical bacteria Bordetella pertussis, Chlamydophila pneumoniae, and Mycoplasma pneumoniae. Eur J Clin Microbiol Infect Dis. 2014;33:1585–9.CrossRefPubMedPubMedCentral
24.
Zurück zum Zitat Yang HJ. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2019;62:199–205.CrossRefPubMedPubMedCentral Yang HJ. Benefits and risks of therapeutic alternatives for macrolide resistant Mycoplasma pneumoniae pneumonia in children. Korean J Pediatr. 2019;62:199–205.CrossRefPubMedPubMedCentral
25.
Zurück zum Zitat Leng M, Yang J, Zhou J. The molecular characteristics, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae in children. Front Pediatr. 2023;11:1115009.CrossRefPubMedPubMedCentral Leng M, Yang J, Zhou J. The molecular characteristics, diagnosis, and treatment of macrolide-resistant Mycoplasma pneumoniae in children. Front Pediatr. 2023;11:1115009.CrossRefPubMedPubMedCentral
26.
Zurück zum Zitat Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia. Emerg Infect Dis. 2020;26:1382–91.CrossRefPubMedPubMedCentral Chen YC, Hsu WY, Chang TH. Macrolide-resistant Mycoplasma pneumoniae infections in pediatric community-acquired pneumonia. Emerg Infect Dis. 2020;26:1382–91.CrossRefPubMedPubMedCentral
27.
Zurück zum Zitat Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol. 2016;7:693.CrossRefPubMedPubMedCentral Yamazaki T, Kenri T. Epidemiology of Mycoplasma pneumoniae infections in Japan and therapeutic strategies for macrolide-resistant M. pneumoniae. Front Microbiol. 2016;7:693.CrossRefPubMedPubMedCentral
28.
Zurück zum Zitat Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53:e25–76.CrossRefPubMed Bradley JS, Byington CL, Shah SS, Alverson B, Carter ER, Harrison C, et al. The management of community-acquired pneumonia in infants and children older than 3 months of age: clinical practice guidelines by the pediatric infectious diseases society and the infectious diseases society of America. Clin Infect Dis. 2011;53:e25–76.CrossRefPubMed
29.
Zurück zum Zitat Shah SS. Mycoplasma pneumoniae as a cause of community-acquired pneumonia in children. Clin Infect Dis. 2018;68:13–4. Shah SS. Mycoplasma pneumoniae as a cause of community-acquired pneumonia in children. Clin Infect Dis. 2018;68:13–4.
30.
Zurück zum Zitat Yang MC, Su YT, Chen PH, Tsai CC, Lin TI, Wu JR. Changing patterns of infectious diseases in children during the COVID-19 pandemic. Front Cell Infect Microbiol. 2023;13:1200617.CrossRefPubMedPubMedCentral Yang MC, Su YT, Chen PH, Tsai CC, Lin TI, Wu JR. Changing patterns of infectious diseases in children during the COVID-19 pandemic. Front Cell Infect Microbiol. 2023;13:1200617.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Li Y, Wang X, Msosa T, de Wit F, Murdock J, Nair H. The impact of the 2009 influenza pandemic on the seasonality of human respiratory syncytial virus: a systematic analysis. Influenza Other Respir Viruses. 2021;15:804–12.CrossRefPubMedPubMedCentral Li Y, Wang X, Msosa T, de Wit F, Murdock J, Nair H. The impact of the 2009 influenza pandemic on the seasonality of human respiratory syncytial virus: a systematic analysis. Influenza Other Respir Viruses. 2021;15:804–12.CrossRefPubMedPubMedCentral
32.
Zurück zum Zitat Cheong JG, Ravishankar A, Sharma S, Parkhurst CN, Grassmann SA, Wingert CK, et al. Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. Cell. 2023;186:3882–902.e24.CrossRefPubMed Cheong JG, Ravishankar A, Sharma S, Parkhurst CN, Grassmann SA, Wingert CK, et al. Epigenetic memory of coronavirus infection in innate immune cells and their progenitors. Cell. 2023;186:3882–902.e24.CrossRefPubMed
33.
Zurück zum Zitat Santopaolo M, Gregorova M, Hamilton F, Arnold D, Long A, Lacey A, et al. Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months. Elife. 2023;12:e85009.CrossRefPubMedPubMedCentral Santopaolo M, Gregorova M, Hamilton F, Arnold D, Long A, Lacey A, et al. Prolonged T-cell activation and long COVID symptoms independently associate with severe COVID-19 at 3 months. Elife. 2023;12:e85009.CrossRefPubMedPubMedCentral
34.
Zurück zum Zitat Odeh AN, Simecka JW. Regulatory CD4+CD25+ T cells dampen inflammatory disease in murine Mycoplasma pneumonia and promote IL-17 and IFN-γ responses. PLoS ONE. 2016;11:e0155648.CrossRefPubMedPubMedCentral Odeh AN, Simecka JW. Regulatory CD4+CD25+ T cells dampen inflammatory disease in murine Mycoplasma pneumonia and promote IL-17 and IFN-γ responses. PLoS ONE. 2016;11:e0155648.CrossRefPubMedPubMedCentral
Metadaten
Titel
Current Mycoplasma pneumoniae epidemic among children in Shanghai: unusual pneumonia caused by usual pathogen
verfasst von
Xiao-Bo Zhang
Wen He
Yong-Hao Gui
Quan Lu
Yong Yin
Jian-Hua Zhang
Xiao-Yan Dong
Ying-Wen Wang
Ying-Zi Ye
Hong Xu
Jia-Yu Wang
Bing Shen
Dan-Ping Gu
Li-Bo Wang
Yi Wang
Publikationsdatum
17.01.2024
Verlag
Springer Nature Singapore
Erschienen in
World Journal of Pediatrics / Ausgabe 1/2024
Print ISSN: 1708-8569
Elektronische ISSN: 1867-0687
DOI
https://doi.org/10.1007/s12519-023-00793-9

Weitere Artikel der Ausgabe 1/2024

World Journal of Pediatrics 1/2024 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.